BEKE vs ESS

BEKE's deterministic health scores signal significant distress: the Piotroski F-Score of 3/9 indicates weak financial health, with deteriorating profitability and negative earnings growth. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given the company's declining earnings and high payout ratio. While the Graham Number ($9.15) suggests undervaluation, the current price of $16.90 trades at a substantial premium, reflecting overoptimistic growth expectations. Analysts recommend 'buy' with a target of $20.68, but this is inconsistent with the company's weak fundamentals and negative earnings trajectory. The stock has underperformed over multiple time horizons, including a 5-year decline of 73.3%.

ESS exhibits significant valuation misalignment, trading at $255.37 despite a Graham Number of $141.78 and an Intrinsic Value of $72.73. The Piotroski F-Score of 4/9 indicates only stable health, while a crashing YoY earnings growth of -68.70% and a PEG ratio of 7.02 suggest the stock is severely overpriced relative to its growth profile. Furthermore, a dividend payout ratio of 98.85% leaves virtually no margin for error, making the current yield precarious. The combination of a 0/100 technical trend and deteriorating earnings fundamentals supports a bearish outlook.